Welcome to our dedicated page for CervoMed news (Ticker: CRVO), a resource for investors and traders seeking the latest updates and insights on CervoMed stock.
CervoMed Inc. reports clinical-stage biotechnology developments centered on neflamapimod, an oral small-molecule drug candidate for age-related brain disorders. Company news most often covers dementia with Lewy bodies, the Phase 2b RewinD-LB trial, biomarker and MRI analyses, pharmacokinetic work, formulation and dosing disclosures, and regulatory interactions tied to later-stage development.
Updates also include financial results, grant revenue trends, investor conference presentations, shareholder voting matters, governance items, and capital-structure disclosures. CervoMed has also reported neflamapimod's inclusion in the UK EXPERTS-ALS platform for amyotrophic lateral sclerosis research.
CervoMed (CRVO)/b) will present initial biomarker results from its Phase 2a clinical trial of neflamapimod in nonfluent variant primary progressive aphasia (nfvPPA) as a late-breaking oral session at the International Society of Frontotemporal Dementias (ISFTD) Annual Meeting in Philadelphia on October 11, 2026.The abstract acceptance was based on 12-week biomarker data from the trial’s first eight participants and the presentation will highlight initial 12-week results for two plasma biomarkers, neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP), from at least 22 study participants. The 25-patient Phase 2a trial, conducted at academic medical centers in the U.S. and U.K., is evaluating the safety, pharmacokinetics, and clinical effects of oral neflamapimod in nfvPPA, a type of frontotemporal dementia commonly associated with tau pathology that currently has no approved treatments in the U.S. or European Union.
The talk, titled “Initial Biomarker Results from a Phase 2a Clinical Trial of Neflamapimod in Patients with Nonfluent Variant Primary Progressive Aphasia (NCT07033481)”, is scheduled in Plenary 6 (Hot Topics) on Sunday, October 11, 2026, from 8:30 a.m. to 10:30 a.m. ET.
CervoMed (CRVO) will participate in two investor conferences in September 2026.
Management plans a fireside chat and 1x1 investor meetings at the Cantor Global Healthcare Conference on Friday, September 11, 2026, from 10:55 to 11:25 AM ET. The company will also give a presentation and hold 1x1 meetings at the H.C. Wainwright Global Investment Conference on Tuesday, September 15, 2026, from 4:00 to 4:30 PM ET, both with live webcasts available.
CervoMed (NASDAQ: CRVO) reported second quarter 2026 results and clinical progress for neflamapimod in dementia with Lewy bodies (DLB) and other indications. The company obtained a UK ILAP Innovation Passport for DLB, received a U.S. patent allowance extending DLB protection into 2042, and presented new RewinD-LB analyses at AAIC 2026 supporting a 50 mg TID dose and showing exposure- and biomarker‑linked CDR‑SB and MRI effects.
CervoMed completed enrollment in its Phase 2a nfvPPA trial and stopped enrollment in the RESTORE stroke trial. It raised about $20.5 million in June equity financings, ending June 30, 2026 with $24.9 million in cash and securities and runway through Q3 2027. Q2 R&D and G&A expenses declined year over year, while net loss was $6.6 million versus $6.3 million in 2025, mainly due to the absence of prior‑year grant revenue.
CervoMed (NASDAQ: CRVO), a clinical-stage biotech focused on age-related brain disorders, will participate in a fireside chat and one-on-one investor meetings at the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11, 2026. Management plans to discuss recent progress in the neflamapimod clinical development program. The fireside chat is scheduled from 11:30–11:55 AM ET and will be available via webcast, including through the Investor section of the CervoMed website.
CervoMed (NASDAQ: CRVO) reported that its oral small-molecule candidate neflamapimod, which targets neuroinflammation in degenerative brain disorders, has been granted an Innovation Passport to enter the UK Innovative Licensing and Access Pathway (ILAP) for the treatment of dementia with Lewy bodies (DLB).
According to CervoMed, ILAP selection reflects joint consensus that neflamapimod is an innovative therapy addressing a high unmet need with potential major therapeutic advantage. The designation offers early, coordinated guidance and priority access to support from the MHRA, NHS, and UK health technology assessment bodies as the company prepares a planned Phase 3 DLB trial.
CervoMed (NASDAQ: CRVO) reported new clinical, plasma biomarker and MRI data for neflamapimod in dementia with Lewy bodies (DLB) at AAIC 2026. New analyses from the 159‑patient Phase 2b RewinD‑LB trial link treatment benefit to “pure” DLB patients with low plasma pTau181 and adequate drug exposure, and support a 50 mg three‑times‑daily dose for planned Phase 3 studies aligned with US and European regulators.
Neflamapimod was associated with durable slowing of right basal forebrain atrophy and increased basal forebrain connectivity versus placebo. A pharmacokinetic‑pharmacodynamic analysis identified a ~4 ng/mL plasma trough threshold tied to clinical and biomarker improvements. A separate 24‑week Phase 2 study in 26 patients showed an 80 mg twice‑daily dose met primary safety, tolerability and pharmacokinetic objectives, with encouraging but open‑label clinical activity signals.
CervoMed (NASDAQ: CRVO) completed enrollment in its Phase 2a study of neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA), a form of frontotemporal dementia.
The 25-patient trial assesses safety, pharmacokinetics and clinical effects, with interim biomarker data to be presented at CTAD 2026 and preclinical support published in Nature Neuroscience.
CervoMed (NASDAQ: CRVO) will feature five scientific presentations at the Alzheimer’s Association International Conference (AAIC) 2026 in London, July 12-15.
Four presentations focus on neflamapimod in dementia with Lewy bodies (DLB), covering disease progression, MRI biomarkers, exposure-response, and 80 mg BID dosing, plus a new DLB goal attainment tool.
CervoMed (NASDAQ: CRVO) closed a $10 million registered direct offering of common stock priced at-the-market under Nasdaq rules. The company sold 2,500,000 shares at $4.00 per share, with H.C. Wainwright & Co. as exclusive placement agent.
CervoMed plans to use net proceeds for working capital and general corporate purposes. The securities were issued under an effective Form S-3 shelf registration statement, with a final prospectus supplement filed with the SEC.
CervoMed (NASDAQ: CRVO) entered definitive agreements for a registered direct offering of 2,500,000 common shares at $4.00 per share, priced at-the-market under Nasdaq rules.
Gross proceeds are expected to be $10 million, closing around June 22, 2026, with funds for working capital and general corporate purposes.